发明授权
US07022729B2 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
失效
氨基环己烷NMDA,5HT3和神经元烟碱受体拮抗剂的Azabicyclic,azatricyclic和azaspirocyclic衍生物
- 专利标题: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
- 专利标题(中): 氨基环己烷NMDA,5HT3和神经元烟碱受体拮抗剂的Azabicyclic,azatricyclic和azaspirocyclic衍生物
-
申请号: US10394670申请日: 2003-03-21
-
公开(公告)号: US07022729B2公开(公告)日: 2006-04-04
- 发明人: Christopher Graham Raphael Parsons , Markus Henrich , Wojciech Danysz , Ivars Kalvinsh , Valerjans Kauss , Aigars Jirgensons , Markus Gold , Maksims Vanejevs
- 申请人: Christopher Graham Raphael Parsons , Markus Henrich , Wojciech Danysz , Ivars Kalvinsh , Valerjans Kauss , Aigars Jirgensons , Markus Gold , Maksims Vanejevs
- 申请人地址: DE Franfurt am Main
- 专利权人: Merz Pharma GmbH & Co. KGAA
- 当前专利权人: Merz Pharma GmbH & Co. KGAA
- 当前专利权人地址: DE Franfurt am Main
- 代理机构: Hueschen and Sage
- 主分类号: A61K31/40
- IPC分类号: A61K31/40 ; C07D209/02
摘要:
Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.